ReviewNature protocols2026
Large-scale genome structure interrogation via recombinase-mediated rearrangements of multiplexed prime edits in repetitive elements.
Review in Nature protocols, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Large-scale interrogation of genome structure is crucial for understanding how genomic organization influences cellular function, yet existing methods are limited by the low density of achievable modifications or the toxicity of methods. Here we address this gap by presenting a versatile approach that combines gene editing and recombinase technologies. The protocol serves two critical purposes: (1) facilitating the introduction of hundreds to thousands of precise genomic edits per cell and (2) enabling the creation of a controlled platform to systematically investigate the effects of induced genomic rearrangements. Specifically, the method leverages prime editing to insert recombinase recognition sites (for example, loxP) into repetitive genomic regions, such as LINE-1 elements, thereby enabling extensive genetic modifications in human cells. This scale of genome editing has not previously been attainable and supports a wide range of studies, including genome-wide functional analyses and essentiality mapping. Inducing controlled rearrangements with recombinase and tracking cell survival under selective conditions allows direct mapping of genome architecture to cellular fitness, opening new opportunities for genome-wide functional screens and rational synthetic genome design. Unlike methods that rely on double-strand breaks or random transposon insertion, this Protocol supports a programmable installation of thousands of recombination sites at repeat elements, offering denser and more predictable substrates for controlled genome rearrangement. The full protocol takes ~12-18 weeks to complete and requires intermediate to advanced expertise in genome editing, mammalian cell culture and sequencing analysis.
Identifiers
42481864What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.